Back

Radiofrequency ablation remodels the tumor microenvironment and promotes systemic immunomodulation in pancreatic cancer

Faraoni, E. Y.; Thosani, N. C.; O'Brien, B.; Strickland, L. N.; Mota, V. Y.; Chaney, J. K.; Cen, P.; Rowe, J.; Cardenas, J. C.; Poulsen, K. L.; Wray, C. J.; Bailey-Lundberg, J.

2022-01-10 cancer biology
10.1101/2022.01.07.475451 bioRxiv
Show abstract

Background and AimsPancreatic ductal adenocarcinoma (PDAC) is characterized by resistance to therapy. A major contributing factor to therapeutic failure is profound desmoplasia and a well-documented hypoxic tumor microenvironment (TME). In PDAC, several therapeutic approaches, including chemotherapy and radiation alone or combined with immune checkpoint inhibitors, have shown minimal therapeutic success, placing an imperative need for the discovery and application of innovative treatments. Endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) is a promising immunomodulator therapy for PDAC. In this work, we hypothesized RFA promotes local and systemic stromal and immunomodulating effects that can be identified for new combination therapeutic strategies. MethodsTo test our hypothesis, a syngeneic PDAC mouse model was performed by symmetrically injecting 100k murine KPC cells in bilateral flanks of C57BL/6 female mice. RFA treatment initiated when tumors reached 200-500 mm3 and was performed only in the right flank. The left flank tumor (non-RFA contralateral side) was used as a paired control for further analysis. ResultsRFA promoted a significant reduction in tumor growth rate 4 days after treatment in RFA treated and non-RFA side contralateral tumors from treated mice when compared to controls. Histological analysis revealed a significant increase in expression of cleaved Caspase3 in RFA treated tumors. In addition, collagen deposition and CD31+ cells were significantly elevated in RFA side and non-RFA contralateral tumors from RFA treated mice. Proteome profiling showed changes in C5a and IL-23 in RFA responsive tumors, indicating a role of RFA in modulating intratumoral inflammatory responses. ConclusionsThese data indicate RFA promotes local and systemic anti-tumor responses in a syngeneic mouse model of PDAC implicating RFA treatment for local tumors as well as metastatic disease. Graphical Abstract O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
BMC Cancer
52 papers in training set
Top 0.1%
23.2%
2
Scientific Reports
3102 papers in training set
Top 9%
8.7%
3
PLOS ONE
4510 papers in training set
Top 24%
7.0%
4
Journal of Translational Medicine
46 papers in training set
Top 0.1%
5.0%
5
Frontiers in Oncology
95 papers in training set
Top 0.6%
5.0%
6
Cancer Medicine
24 papers in training set
Top 0.3%
3.8%
50% of probability mass above
7
PeerJ
261 papers in training set
Top 2%
3.8%
8
Diagnostics
48 papers in training set
Top 0.6%
2.8%
9
Cancers
200 papers in training set
Top 2%
2.7%
10
Computers in Biology and Medicine
120 papers in training set
Top 1%
2.4%
11
Cancer Research Communications
46 papers in training set
Top 0.5%
1.5%
12
British Journal of Cancer
42 papers in training set
Top 0.9%
1.5%
13
Medicine
30 papers in training set
Top 1%
1.4%
14
Heliyon
146 papers in training set
Top 4%
1.0%
15
Neoplasia
22 papers in training set
Top 0.5%
0.8%
16
F1000Research
79 papers in training set
Top 4%
0.8%
17
Signal Transduction and Targeted Therapy
29 papers in training set
Top 1%
0.8%
18
Nature Communications
4913 papers in training set
Top 62%
0.8%
19
Molecular & Cellular Proteomics
158 papers in training set
Top 2%
0.8%
20
Informatics in Medicine Unlocked
21 papers in training set
Top 1%
0.8%
21
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.8%
22
JNCI Cancer Spectrum
10 papers in training set
Top 0.5%
0.8%
23
JNCI: Journal of the National Cancer Institute
16 papers in training set
Top 0.6%
0.8%
24
Biochemistry and Biophysics Reports
28 papers in training set
Top 1%
0.8%
25
International Journal of Molecular Sciences
453 papers in training set
Top 16%
0.7%
26
Gastroenterology
40 papers in training set
Top 2%
0.7%
27
Journal of Clinical Medicine
91 papers in training set
Top 8%
0.5%
28
Translational Oncology
18 papers in training set
Top 0.5%
0.5%
29
Molecular Cancer Therapeutics
33 papers in training set
Top 0.8%
0.5%